4,5-Diethyl-2-pyridone | 85995-60-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4,5-Diethyl-2-pyridone
• 英文别名: 4,5-Diethyl-2-pyridon；4,5-diethyl-1H-pyridin-2-one；4,5-diethyl-1H-pyridin-2-one
• CAS: 85995-60-4
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: XBXPQGQCOGAZRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  7,8-diethyl-2,4-diaza-bicyclo[4.2.0]oct-7-ene-3,5-dione 在 potassium tert-butylate 作用下， 以 叔丁醇 为溶剂， 反应 25.0h， 以67%的产率得到4,5-Diethyl-2-pyridone
  参考文献：
  名称：

  Anion-mediated fragmentation reactions. Mechanistic and synthetic aspects of the fragmentation and rearrangement reactions of pyrimidinedione-alkyne photoadducts

  摘要：

  DOI：

  10.1021/jo00162a008

文献信息

• 1,2-Disubstituted Heterocyclic Compounds
  申请人：Ripka Amy

  公开号：US20120232265A1

  公开（公告）日：2012-09-13

  1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

  本文描述了抑制磷酸二酯酶10的1,2-二取代杂环化合物。还描述了这些化合物的制备方法、制药组合物、制药制剂以及在治疗哺乳动物（包括人类）中枢神经系统（CNS）疾病和其他可能影响CNS功能的疾病中使用这些化合物的制药用途。可以治疗的疾病包括神经、神经退行性和精神障碍，包括但不限于与认知缺陷或精神分裂症状相关的疾病。
• COMBER R. N.; SWENTON J. S.; WEXLER A. J., J. AMER. CHEM. SOC., 1979, 101, NO 18, 5411-5412
  作者：COMBER R. N.、 SWENTON J. S.、 WEXLER A. J.

  DOI：——

  日期：——
• KAMINSKI, V. V.;COMBER, R. N.;WEXLER, A. J.;SWENTON, J. S., J. ORG. CHEM., 1983, 48, N 14, 2337-2346
  作者：KAMINSKI, V. V.、COMBER, R. N.、WEXLER, A. J.、SWENTON, J. S.

  DOI：——

  日期：——
• BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS
  申请人：Chackalamannil Samuel

  公开号：US20120157403A1

  公开（公告）日：2012-06-21

  Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R 3 , R 10 , R 11 , R 32 and R 33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.